title: Pre- and postsynaptic mechanisms underlying inhibition of hypoglossal motor neuron excitability by riluzole.
abstract: Riluzole is the sole treatment for amyotrophic lateral sclerosis (ALS), but its therapeutically relevant actions on motor neurons are not well defined. Whole cell patch-clamp recordings were made from hypoglossal motor neurons (HMs, n = 25) in brain stem slices from 10- to 23-day-old rats anesthetized with pentobarbital sodium to investigate the hypothesis that riluzole inhibits HMs by multiple mechanisms. Riluzole (20 μM) hyperpolarized HMs by decreasing an inward current, inhibited voltage-gated persistent Na(+) and Ca(2+) currents activated by slow voltage ramps, and negatively shifted activation of the hyperpolarization-activated cationic current (IH). Repetitive firing of HMs was strongly inhibited by riluzole, which also increased action potential threshold voltage and rheobase and decreased amplitude and maximum rise slope but did not alter the maximal afterhyperpolarization amplitude or decay time constant. HM rheobase was inversely correlated with persistent Na(+) current density. Glutamatergic synaptic transmission was inhibited by riluzole by both pre- and postsynaptic effects. Riluzole decreased activity-dependent glutamate release, as shown by decreased amplitude of evoked and spontaneous excitatory postsynaptic currents (EPSCs), decreased paired-pulse ratio, and decreased spontaneous, but not miniature, EPSC frequency. However, riluzole also decreased miniature EPSC amplitude and the inward current evoked by local application of glutamate onto HMs, suggesting a reduction of postsynaptic glutamate receptor sensitivity. Riluzole thus has a marked inhibitory effect on HM activity by membrane hyperpolarization, decreasing firing and inhibiting glutamatergic excitation by both pre- and postsynaptic mechanisms. These results broaden the range of mechanisms controlling motor neuron inhibition by riluzole and are relevant to researchers and clinicians interested in understanding ALS pathogenesis and treatment.
authors.affiliation: School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia. mark.bellingham@uq.edu.au
authors.forename: Mark C
authors.initials: MC
authors.lastname: Bellingham
mesh_terms: D000818:Animals; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects*; D005260:Female; D007002:Hypoglossal Nerve / Q000166:cytology; D066298:In Vitro Techniques; D008297:Male; D008526:Medulla Oblongata / Q000502:physiology*; D009046:Motor Neurons / Q000502:physiology*; D051381:Rats; D019782:Riluzole / Q000494:pharmacology*; D013569:Synapses / Q000502:physiology*
chemical_list: D018691:Excitatory Amino Acid Antagonists; D019782:Riluzole
keywords: amyotrophic lateral sclerosis; excitatory synaptic transmission; hyperpolarization-activated cation current; ionotropic glutamate receptor; persistent sodium current